ArticleJournal of dental sciences2017
Fabrication and characterization of polycaprolactone and tricalcium phosphate composites for tissue engineering applications.
Article in Journal of dental sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 48 citations in OpenAlex.
- Healing Kinetics of Sinus Lift Augmentation Using Biphasic Calcium Phosphate Granules: A Case Series in Humans.Bioengineering (Basel, Switzerland) · 2025Article
- Direct inkjet writing of polylactic acid/β-tricalcium phosphate composites for bone tissue regeneration: A proof-of-concept study.Journal of biomedical materials research. Part B, Applied biomaterials · 2024Article
- 3D printed polycaprolactone/β-tricalcium phosphate/carbon nanotube composite - Physical properties and biocompatibility.Heliyon · 2024Article
- Article
- An osteoinductive and biodegradable intramedullary implant accelerates bone healing and mitigates complications of bone transport in male rats.Nature communications · 2023Article
- Evaluation of osteoconductive effect of polycaprolactone (PCL) scaffold treated withAmerican journal of stem cells · 2023Article
- Composite Fibers Based on Polycaprolactone and Calcium Magnesium Silicate Powders for Tissue Engineering Applications.Polymers · 2022Article
- Modifications in Gene Expression in the Process of Osteoblastic Differentiation of Multipotent Bone Marrow-Derived Human Mesenchymal Stem Cells Induced by a Novel Osteoinductive Porous Medical-Grade 3D-Printed Poly(ε-caprolactone)/β-tricalcium Phosphate Composite.International journal of molecular sciences · 2021Article
- Clinical Efficacy of Polycaprolactone β-Calcium Triphosphate Composite for Osteoconduction in Rabbit Bone Defect Model.Polymers · 2021Article
- 3D-Printed Barrier Membrane Using Mixture of Polycaprolactone and Beta-Tricalcium Phosphate for Regeneration of Rabbit Calvarial Defects.Materials (Basel, Switzerland) · 2021Article
- Histomorphometric Evaluation of Bone-Guided Regeneration in Maxillary Sinus Floor Augmentation Using Nano-Hydroxyapatite/Beta-Tricalcium Phosphate Composite Biomaterial: A Case Report.International medical case reports journal · 2021Article
- PLA-Based Mineral-Doped Scaffolds Seeded with Human Periapical Cyst-Derived MSCs: A Promising Tool for Regenerative Healing in Dentistry.Materials (Basel, Switzerland) · 2019Article
- Surface Modification of Calcium Silicate via Mussel-Inspired Polydopamine and Effective Adsorption of Extracellular Matrix to Promote Osteogenesis Differentiation for Bone Tissue Engineering.Materials (Basel, Switzerland) · 2018Article
- Bioactive calcium silicate/poly-ε-caprolactone composite scaffolds 3D printed under mild conditions for bone tissue engineering.Journal of materials science. Materials in medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background/purposeβ-Tricalcium phosphate (β-TCP) is an osteoconductive material which has been used for clinical purposes for several years, as is polycaprolactone (PCL), which has already been approved for a number of medical and drug delivery devices. In this study we have incorporated various concentrations of β-TCP into PCL with the aim of developing an injectable, mechanically strong, and biodegradable material which can be used for medical purposes without organic solvents. MATERIALS AND
methodsThis study assesses the physical and chemical properties of this material, evaluates the
resultsThe results show that weight losses of approximately 5.3%, 12.1%, 18.6%, and 25.2%, were observed for the TCP0, TCP10, TCP30, and TCP50 composites after immersion in simulated body fluid for 12 weeks, respectively, indicating significant differences (P < 0.05). In addition, PCL/β-TCP composites tend to have lower contact angles (47 ± 1.5° and 58 ± 1.7° for TCP50 and TCP30, respectively) than pure PCL (85 ± 1.3°), which are generally more hydrophilic. After 7 days, a significant (22% and 34%, respectively) increase (P < 0.05) in alkaline phosphatase level was measured for TCP30 and TCP50 in comparison with the pure PCL.
conclusionPCL/TCP is biocompatible with hBMSCs. It not only promotes proliferation of hBMSCs but also helps to differentiate reparative hard tissue. We suggest 50% (weight) PCL-containing β-TCP biocomposites as the best choice for hard tissue repair applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.